Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Slides:

Advertisements

Similar presentations

이근욱 분당서울대학교병원/서울의대 혈액종양내과 부교수

Advertisements

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.

Bijoy Telivala, MD Advances in Immunotherapy Bijoy Telivala, MD

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Metastatic Head Neck Cancer and Immunotherapy

Management of metastatic and recurrent head and neck cancer

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Bladder Cancer: A New Era in Treatment

Evolving Paradigms in Recurrent/Metastatic SCCHN

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Treatment Algorithms in Melanoma: Past, Present, and Future

The Immune System. The Immune System Adaptive Immune Response.

Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Discussion Outline Cells of the Immune System.

Immunotherapy Combinations for Lung Cancers

Spotlight on Immuno-Oncology in Melanoma

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Updates in Lung Cancer: Insights From Vienna

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Activity Goals. Activity Goals Discussion Topics.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Management of Glioblastoma

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Basics of Immunotherapy Potential Therapeutic Targets.

Treating mRCC After Initial Antiangiogenic Therapy:

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Advanced Lung Cancers: What's on the Horizon?

More Than Meets the Eye.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Activity Goals. Activity Goals Program Overview.

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

PARP Inhibitors.

Advances in Gastrointestinal Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Targeting T Cell Co-receptors for Cancer Therapy

Progress of the NSCLC Revolution

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Preparing for Checkpoint Inhibitors in Breast Cancer

Novel Concepts in the Management of RCC

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

Activity Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Genitourinary Cancers.

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

TGF-β Inhibition and Immunotherapy: Checkmate

Taking a Closer Look at Recurrent/Metastatic SCCHN

Going Beyond EXTREME in Head and Neck Cancer

Moving Care Forward in Advanced Gastric Cancer

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Clinical Focus.

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View.

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Recent Developments in the Treatment of Advanced and Metastatic RCC

Presentation transcript:

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer

1899: Coley’s Toxin

2016: PD-1 Inhibition

2016: PD-1 Inhibition

Overview

Tumor Immunology Cycle

The Yin and Yang of Immune Escape

Cancer Is Highly Immunosuppressive

T Cells Killing a Tumor Cell

Inflamed Phenotype in HNC TILs

Inflamed/Mesenchymal Intrinsic HNC Subtype

Clinical Activity

Recurrent and/or Metastatic HNC

Some of the PD-1/PD-L1 and CTLA-4 Targeting Agents in Development

KEYNOTE-055: Phase 2 Trial of Pembrolizumab After Progression

KEYNOTE-055: ORR

EXTREME vs Immunotherapy The Tail at the End of the Curve

Tumor Shrinkage

Case Study

Case Study (cont)

CheckMate 141: Phase 3 Trial of Nivolumab After Progression

CheckMate 141: OS

How Do We Select Patients? Biomarkers

PD-L1 Expression in Head and Neck Cancer

CheckMate 141: OS by Tumor PD-L1 Expression

Association of IFN-γ Signature and PFS

PFS and OS by IFN-γ 6-Gene Signature Score

CheckMate 141: OS by p16 Status

Adverse Effect Management

KEYNOTE-055: TRAEs With Pembrolizumab

Overview of irAEs

The Future: Immunotherapy Combinations

Combination Therapy

Immunotherapy in the First-Line Setting

Immunotherapy in the First-Line Setting (cont)

Immunotherapy in the First-Line Setting (cont)

Making Tumors Inflamed: T-VEC

Changing the Immunosuppressive ME: IDO

Ongoing and Future Clinical Concepts

Take-Home Messages

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)